Ali has been serving as General Counsel since mid-April 2022. She has more than 14 years of corporate and legal expertise. She has been with NeoGenomics for over 5 years, representing the company in its acquisition of Inivata and Trapelo Health, as well as fundraising and governance activities. At NeoGenomics, she has also represented the company in various regulatory matters, including before the College of American Pathologists (CAP), the Office for Civil Rights (OCR), and the Office of Inspector General (OIG).
Prior to joining NeoGenomics, Ali served as a Director at PricewaterhouseCoopers, LLP, negotiating incentives for numerous Fortune 500 clients. She also spent many years at General Electric in various roles increasing in scope and responsibility, including Counsel, where she oversaw incentives negotiations, tax controversy, and government affairs.